Company Description
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States.
The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. is headquartered in South San Francisco, California.
Contact Details
Address: 170 Harbor Way, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 550 3500 |
| Website | vaxart.com |
Stock Details
| Ticker Symbol | VXRT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000072444 |
| CUSIP Number | 92243A200 |
| ISIN Number | US92243A2006 |
| Employer ID | 59-1212264 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Steven Lo | President, Chief Executive Officer and Director |
| Dr. Sean N. Tucker Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. James F. Cummings M.D. | Chief Medical Officer |
| Jeroen Grasman M.B.A. | Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer |
| Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer |
| Edward B. Berg | Senior Vice President and General Counsel |
| Laurie Hastings | Senior Vice President of Human Resources |
| Shaily Jaini Garg | Senior Vice President of Clinical Development and Project Management |
| Dr. Rajesh Kapoor Ph.D. | Senior Vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 6, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 6, 2025 | 8-K | Current Report |
| Jul 24, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 8, 2025 | 8-K | Current Report |
| Jul 2, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |